{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T22:18:13Z","timestamp":1776896293686,"version":"3.51.2"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Nonsteroidal antiinf lammatory drugs (NSAIDs) remain the mainstay of the pharmacologic management for relieving osteoarthritis pain, and low-dose aspirin is often prescribed to osteoarthritis patients who are at high risk of cardiovascular disease (CVD). We conducted cohort studies using data from The Health Improvement Network (THIN) database (2000\u20132019) to assess whether the relationship of initiation of naproxen or ibuprofen vs. initiation of other NSAIDs (excluding both naproxen and ibuprofen), respectively, to the risk of CVD was modified by coprescription of low-dose aspirin among the participants with osteoarthritis. Among participants without coprescription of aspirin, the risk of CVD was lower in naproxen initiators (10.3\/1000 person-years) than in other NSAIDs initiators (13.2\/1000 person-years; hazard ratio\u00a0= 0.71, 95% confidence interval: 0.60, 0.85). Among participants with coprescription of aspirin, however, the risk of CVD was higher among naproxen initiators (36.9\/1000 person-years) than that among other NSAIDs initiators (34.8\/1000 person-years; hazard ratio\u00a0= 1.48, 95% confidence interval: 1.12, 1.84). The association was significantly modified by coprescription of aspirin (P\u00a0&amp;lt; 0.001). Similar findings were observed in the association of initiation of ibuprofen vs. other NSAIDs with the risk of CVD, which was significantly modified by coprescription of aspirin (P\u00a0&amp;lt; 0.001). These findings suggest that osteoarthritis patients and clinicians should be aware of the potential CVD risk of concurrently taking naproxen or ibuprofen and low-dose aspirin.<\/jats:p>","DOI":"10.1093\/aje\/kwad094","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T05:42:25Z","timestamp":1681882945000},"page":"1432-1448","source":"Crossref","is-referenced-by-count":8,"title":["Interactions of Nonsteroidal Antiinflammatory Drugs and Aspirin and Risk of Cardiovascular Disease in Patients With Osteoarthritis"],"prefix":"10.1093","volume":"192","author":[{"given":"Jie","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy E","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanghua","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"issue":"2","key":"2023090110150160200_ref1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/art.41142","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee","volume":"72","author":"Kolasinski","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"2023090110150160200_ref2","doi-asserted-by":"crossref","first-page":"e721","DOI":"10.5435\/JAAOS-D-21-01233","article-title":"AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition","volume":"30","author":"Brophy","year":"2022","journal-title":"J Am Acad Orthop Surg"},{"issue":"2","key":"2023090110150160200_ref3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40256-016-0200-5","article-title":"Clinical pharmacology and cardiovascular safety of naproxen","volume":"17","author":"Angiolillo","year":"2017","journal-title":"Am J Cardiovasc Drugs"},{"issue":"10","key":"2023090110150160200_ref4","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.2019.1347","article-title":"Association of tramadol with all-cause mortality among patients with osteoarthritis","volume":"321","author":"Zeng","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"2023090110150160200_ref5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/rheumatology\/keaa244","article-title":"Initial analgesic prescriptions for osteoarthritis in the United Kingdom, 2000\u20132016","volume":"60","author":"Zeng","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"2023090110150160200_ref6","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/jgs.17038","article-title":"Age-related trajectories of cardiovascular risk and use of aspirin and statin among U.S. adults aged 50 or older, 2011\u20132018","volume":"69","author":"Rhee","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"2023090110150160200_ref7","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/acr.24008","article-title":"Comorbidities in osteoarthritis: a systematic review and meta-analysis of observational studies","volume":"72","author":"Swain","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023090110150160200_ref8","article-title":"Fifty years with aspirin and platelets","author":"Patrono","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"8","key":"2023090110150160200_ref9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nsb0895-637","article-title":"The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase","volume":"2","author":"Loll","year":"1995","journal-title":"Nat Struct Biol"},{"key":"2023090110150160200_ref10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.vph.2016.10.006","article-title":"Aspirin, stroke and drug-drug interactions","volume":"87","author":"Russo","year":"2016","journal-title":"Vascul Pharmacol"},{"issue":"11","key":"2023090110150160200_ref11","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41569-019-0225-y","article-title":"Role of aspirin in primary prevention of cardiovascular disease","volume":"16","author":"Patrono","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"2023090110150160200_ref12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11239-018-1764-5","article-title":"A narrative review of the cardiovascular risks associated with concomitant aspirin and NSAID use","volume":"47","author":"Gurbel","year":"2019","journal-title":"J Thromb Thrombolysis"},{"issue":"7","key":"2023090110150160200_ref13","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.3390\/ph3072146","article-title":"Non-steroidal anti-inflammatory drugs: an overview of cardiovascular risks","volume":"3","author":"Meek","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"2023090110150160200_ref14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00228-012-1370-y","article-title":"Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study","volume":"69","author":"Meek","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"25","key":"2023090110150160200_ref15","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"2023090110150160200_ref16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/0091270007310379","article-title":"Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis","volume":"48","author":"Gengo","year":"2008","journal-title":"J Clin Pharmacol"},{"issue":"9357","key":"2023090110150160200_ref17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(03)12509-3","article-title":"Effect of ibuprofen on cardioprotective effect of aspirin","volume":"361","author":"MacDonald","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"2023090110150160200_ref18","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1476-5381.2009.00243.x","article-title":"The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers","volume":"157","author":"Schuijt","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"3","key":"2023090110150160200_ref19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.clpt.2006.05.004","article-title":"Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease","volume":"80","author":"Renda","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2023090110150160200_ref20","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/art.30175","article-title":"Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences","volume":"63","author":"Anzellotti","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2023090110150160200_ref21","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2005.01.045","article-title":"Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects","volume":"45","author":"Capone","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"47","key":"2023090110150160200_ref22","doi-asserted-by":"crossref","first-page":"16830","DOI":"10.1073\/pnas.1406997111","article-title":"Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs","volume":"111","author":"Li","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2023090110150160200_ref23","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.amjcard.2007.11.054","article-title":"The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers","volume":"101","author":"Gladding","year":"2008","journal-title":"Am J Cardiol"},{"issue":"6732","key":"2023090110150160200_ref24","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/bmj.300.6732.1092","article-title":"The Read clinical classification","volume":"300","author":"Chisholm","year":"1990","journal-title":"BMJ"},{"issue":"9596","key":"2023090110150160200_ref25","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"Elm","year":"2007","journal-title":"Lancet"},{"issue":"12","key":"2023090110150160200_ref26","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2020-217782","article-title":"Risk of venous thromboembolism in knee, hip and hand osteoarthritis: a general population-based cohort study","volume":"79","author":"Zeng","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2023090110150160200_ref27","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1002\/art.39246","article-title":"Total joint arthroplasty and the risk of myocardial infarction: a general population, propensity score-matched cohort study","volume":"67","author":"Lu","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2023090110150160200_ref28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/annrheumdis-2017-211811","article-title":"Effect of bisphosphonates on knee replacement surgery","volume":"77","author":"Neogi","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2023090110150160200_ref29","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.joca.2019.05.020","article-title":"Thiazide diuretics and risk of knee replacement surgery among patients with knee osteoarthritis: a general population-based cohort study","volume":"27","author":"Wei","year":"2019","journal-title":"Osteoarthr Cartil"},{"issue":"2","key":"2023090110150160200_ref30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.joca.2019.10.001","article-title":"Association of tramadol with risk of myocardial infarction among patients with osteoarthritis","volume":"28","author":"Wei","year":"2020","journal-title":"Osteoarthr Cartil"},{"key":"2023090110150160200_ref31","volume-title":"Defining and Validating Chronic Diseases: an Administrative Data Approach","author":"Lix","year":"2006"},{"key":"2023090110150160200_ref32","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e4928","article-title":"Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study","volume":"345","author":"Fardet","year":"2012","journal-title":"BMJ"},{"issue":"6","key":"2023090110150160200_ref33","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/pds.1919","article-title":"Validation of ischemic cerebrovascular diagnoses in The Health Improvement Network (THIN)","volume":"19","author":"Ruig\u00f3mez","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"2023090110150160200_ref34","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/pds.3391","article-title":"Incidence of hemorrhagic stroke in the general population: validation of data from The Health Improvement Network","volume":"22","author":"Gaist","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2023090110150160200_ref35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2337\/diacare.28.1.20","article-title":"Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting","volume":"28","author":"Maru","year":"2005","journal-title":"Diabetes Care"},{"issue":"6","key":"2023090110150160200_ref36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"issue":"1","key":"2023090110150160200_ref37","first-page":"1","article-title":"Weighted Cox regression using the R package coxphw","volume":"84","author":"Dunkler","year":"2018","journal-title":"J Stat Softw"},{"issue":"6","key":"2023090110150160200_ref38","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1172\/JCI110576","article-title":"Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects","volume":"69","author":"Patrignani","year":"1982","journal-title":"J Clin Invest"},{"issue":"6","key":"2023090110150160200_ref39","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/01.CIR.72.6.1177","article-title":"Clinical pharmacology of platelet cyclooxygenase inhibition","volume":"72","author":"Patrono","year":"1985","journal-title":"Circulation"}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwad094\/50965220\/kwad094.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/192\/9\/1432\/51319577\/kwad094.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/192\/9\/1432\/51319577\/kwad094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T10:17:32Z","timestamp":1693563452000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/192\/9\/1432\/7128284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,4,19]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwad094","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,4,19]]}}}